BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898. [PMID: 3569765 DOI: 10.1016/0016-5085(87)90621-4] [Cited by in Crossref: 512] [Cited by in F6Publishing: 465] [Article Influence: 14.6] [Reference Citation Analysis]
Number Citing Articles
1 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
2 Suda T, Takahashi M, Katayama Y, Tamano M. COVID-19 pandemic and exacerbation of ulcerative colitis. World J Clin Cases 2021; 9(36): 11220-11227 [DOI: 10.12998/wjcc.v9.i36.11220] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Marsh A, Rindfleish S, Bennett K, Croft A, Chachay V. Outcomes of dietary management approaches in active ulcerative colitis: A systematic review. Clin Nutr 2021;41:298-306. [PMID: 34999323 DOI: 10.1016/j.clnu.2021.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis 2021:jjab218. [PMID: 34850857 DOI: 10.1093/ecco-jcc/jjab218] [Reference Citation Analysis]
5 Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis. J Crohns Colitis 2021:jjab135. [PMID: 34309658 DOI: 10.1093/ecco-jcc/jjab135] [Reference Citation Analysis]
6 Kakuta K, Dohi K, Yamamoto T, Fujimoto N, Shimoyama T, Umegae S, Ito M. Coronary Microvascular Dysfunction Restored After Surgery in Inflammatory Bowel Disease: A Prospective Observational Study. J Am Heart Assoc 2021;10:e019125. [PMID: 33899514 DOI: 10.1161/JAHA.120.019125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hagan M, Hayee BH, Rodriguez-Mateos A. (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. Molecules 2021;26:1843. [PMID: 33805938 DOI: 10.3390/molecules26071843] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
10 Kamal N, Motwani K, Wellington J, Wong U, Cross RK. Fecal Incontinence in Inflammatory Bowel Disease. Crohns Colitis 360 2021;3:otab013. [PMID: 34226891 DOI: 10.1093/crocol/otab013] [Reference Citation Analysis]
11 Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis 2021;15:1184-96. [PMID: 33433562 DOI: 10.1093/ecco-jcc/jjab010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31674-8. [PMID: 33338657 DOI: 10.1016/j.cgh.2020.12.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Marutani Y, Mizoshita T, Sugiyama T, Togawa S, Katano T, Yamada T, Hirata Y, Kimura Y, Miyaki T, Inoue Y, Suzuki E, Sasaki M, Kataoka H. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice. Indian J Gastroenterol 2020;39:565-75. [PMID: 33106991 DOI: 10.1007/s12664-020-01092-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Ahamed Z R, Dutta U, Sharma V, Prasad KK, Popli P, Kalsi D, Vaishnavi C, Arora S, Kochhar R. Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial. J Clin Gastroenterol 2019;53:e409-15. [PMID: 31356558 DOI: 10.1097/MCG.0000000000001233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Yamamoto T, Shimoyama T, Umegae S, Kotze PG. Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study.Clin Transl Gastroenterol. 2019;10:e00050. [PMID: 31136361 DOI: 10.14309/ctg.0000000000000050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
17 Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis 2020;14:1274-81. [PMID: 32179906 DOI: 10.1093/ecco-jcc/jjaa041] [Reference Citation Analysis]
18 Nakase H, Hirano T, Wagatsuma K, Ichimiya T, Yamakawa T, Yokoyama Y, Hayashi Y, Hirayama D, Kazama T, Yoshii S, Yamano HO. Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis. Dig Endosc. 2020;. [PMID: 32909283 DOI: 10.1111/den.13825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Goulart RDA, Barbalho SM, Rubira CJ, Araújo AC, Lima VM, Buchaim RL, Guiguer EL. Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 2020;14:1171-9. [DOI: 10.1080/17474124.2020.1808460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000543. [PMID: 32786164 DOI: 10.1002/14651858.CD000543.pub5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
23 Dang X, Xu M, Liu D, Zhou D, Yang W. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis. PLoS One. 2020;15:e0228846. [PMID: 32182248 DOI: 10.1371/journal.pone.0228846] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
24 Diab J, Al-Mahdi R, Gouveia-Figueira S, Hansen T, Jensen E, Goll R, Moritz T, Florholmen J, Forsdahl G. A Quantitative Analysis of Colonic Mucosal Oxylipins and Endocannabinoids in Treatment-Naïve and Deep Remission Ulcerative Colitis Patients and the Potential Link With Cytokine Gene Expression. Inflamm Bowel Dis 2019;25:490-7. [PMID: 30476077 DOI: 10.1093/ibd/izy349] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
25 Xie C, Yan W, Quan R, Chen C, Tu L, Hou X, Fu Y. Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation. Cytokine 2020;127:154963. [PMID: 31927461 DOI: 10.1016/j.cyto.2019.154963] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
26 Low END, Mokhtar NM, Wong Z, Raja Ali RA. Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways. J Crohns Colitis 2019;13:755-63. [PMID: 30954025 DOI: 10.1093/ecco-jcc/jjz002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
27 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 30.7] [Reference Citation Analysis]
28 Shakurnia A, Sheikhi A, Mirzapour M, Baharifar V, Baharifar N, Aghamohammadi N, Sheikhi M, Matinrad M, Mousavinasab SN, Sheikhi S, Sheikhi R. Sugarcane molasses enhances TGF-β secretion and FOXP3 gene expression by Bifidobacterium Animalis Subsp. Lactis stimulated PBMCs of Ulcerative Colitis patients. Complement Ther Med 2019;47:102210. [PMID: 31780030 DOI: 10.1016/j.ctim.2019.102210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study. Revista de Gastroenterología de México (English Edition) 2019;84:317-25. [DOI: 10.1016/j.rgmxen.2019.02.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validación de un nuevo índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. Revista de Gastroenterología de México 2019;84:317-25. [DOI: 10.1016/j.rgmx.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Sun M, Du B, Shi Y, Lu Y, Zhou Y, Liu B. Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis. Med Sci Monit 2019;25:3303-15. [PMID: 31055592 DOI: 10.12659/MSM.916009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
32 Yarlas A, D'Haens G, Willian MK, Teynor M. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. Inflamm Bowel Dis. 2018;24:450-463. [PMID: 29361097 DOI: 10.1093/ibd/izx041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
33 Tsuda S, Carreras J, Kikuti YY, Nakae H, Dekiden-Monma M, Imai J, Tsuruya K, Nakamura J, Tsukune Y, Uchida T, Matsushima M, Roncador G, Suzuki T, Nakamura N, Mine T. Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity. Pathol Int 2019;69:260-71. [PMID: 30990953 DOI: 10.1111/pin.12794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Perler BK, Ungaro R, Baird G, Mallette M, Bright R, Shah S, Shapiro J, Sands BE. Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. BMC Gastroenterol 2019;19:47. [PMID: 30940072 DOI: 10.1186/s12876-019-0963-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
35 van der Waal MB, Flach J, Browne PD, Besseling-van der Vaart I, Claassen E, van de Burgwal LH. Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective. PharmaNutrition 2019;7:100139. [DOI: 10.1016/j.phanu.2018.100139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Suzuki T, Mizoshita T, Tanida S, Sugimura N, Katano T, Nishie H, Kataoka H. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH Open 2019;3:217-23. [PMID: 31276039 DOI: 10.1002/jgh3.12140] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Hossen I, Hua W, Ting L, Mehmood A, Jingyi S, Duoxia X, Yanping C, Hongqing W, Zhipeng G, Kaiqi Z, Fang Y, Junsong X. Phytochemicals and inflammatory bowel disease: a review. Crit Rev Food Sci Nutr 2020;60:1321-45. [PMID: 30729797 DOI: 10.1080/10408398.2019.1570913] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
38 Schniers A, Goll R, Pasing Y, Sørbye SW, Florholmen J, Hansen T. Ulcerative colitis: functional analysis of the in-depth proteome. Clin Proteomics 2019;16:4. [PMID: 30718987 DOI: 10.1186/s12014-019-9224-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
39 Heidarian F, Alebouyeh M, Shahrokh S, Balaii H, Zali MR. Altered fecal bacterial composition correlates with disease activity in inflammatory bowel disease and the extent of IL8 induction. Curr Res Transl Med 2019;67:41-50. [PMID: 30685379 DOI: 10.1016/j.retram.2019.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
40 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clin Gastroenterol Hepatol 2019; 17: 1265-1275. e8. [PMID: 30583048 DOI: 10.1016/j.cgh.2018.12.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
42 Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri JC, DiBonaventura MD. Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient Rep Outcomes. 2018;2:62. [PMID: 30547275 DOI: 10.1186/s41687-018-0088-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
43 Fonseca-Camarillo G, Furuzawa-Carballeda J, Iturriaga-Goyon E, Yamamoto-Furusho JK. Differential Expression of IL-36 Family Members and IL-38 by Immune and Nonimmune Cells in Patients with Active Inflammatory Bowel Disease. Biomed Res Int 2018;2018:5140691. [PMID: 30643810 DOI: 10.1155/2018/5140691] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
44 Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. Dig Dis Sci 2019;64:846-54. [PMID: 30426297 DOI: 10.1007/s10620-018-5362-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
45 Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2018;10:E1737. [PMID: 30424514 DOI: 10.3390/nu10111737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
46 Tambuwala MM, Kesharwani P, Shukla R, Thompson PD, Mccarron PA. Caffeic acid phenethyl ester (CAPE) reverses fibrosis caused by chronic colon inflammation in murine model of colitis. Pathology - Research and Practice 2018;214:1909-11. [DOI: 10.1016/j.prp.2018.08.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
47 Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol 2018;12:1079-100. [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Nakamura S, Imaeda H, Nishikawa H, Iimuro M, Matsuura M, Oka H, Oku J, Miyazaki T, Honda H, Watanabe K, Nakase H, Andoh A. Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study. Intest Res 2018;16:554-62. [PMID: 30301337 DOI: 10.5217/ir.2018.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2018;. [PMID: 30130840 DOI: 10.5946/ce.2018.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
51 Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017;11:785-791. [PMID: 28333362 DOI: 10.1093/ecco-jcc/jjx032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
52 Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-biroulet L, D’haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology 2018;16:637-647.e13. [DOI: 10.1016/j.cgh.2017.08.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
53 Ogata H, Yokoyama T, Mizushima S, Hagino A, Hibi T. Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. Intest Res. 2018;16:255-266. [PMID: 29743838 DOI: 10.5217/ir.2018.16.2.255] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
54 Willian MK, D'Haens G, Yarlas A, Joshi AV. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study. J Patient Rep Outcomes 2018;2:22. [PMID: 30294708 DOI: 10.1186/s41687-018-0046-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
56 Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, Kishimoto H, Nambu R, Kagimoto S. Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. J Pediatr Gastroenterol Nutr 2017;64:955-61. [PMID: 27906804 DOI: 10.1097/MPG.0000000000001477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
57 Komoto S, Matsuoka K, Kobayashi T, Yokoyama Y, Suzuki Y, Hibi T, Miura S, Hokari R. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. J Gastroenterol Hepatol 2018;33:1485-91. [PMID: 29406567 DOI: 10.1111/jgh.14116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
58 Onodera M, Endo K, Kakuta Y, Kuroha M, Kimura T, Hiramoto K, Kanazawa Y, Negoro K, Shiga H, Kinouchi Y, Shimosegawa T. ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017;32:1562-1569. [PMID: 28135009 DOI: 10.1111/jgh.13753] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Quezada SM, Briscoe J, Cross RK. Complementary and Alternative Medicine. Inflamm Bowel Dis 2016;22:1523-30. [PMID: 27057686 DOI: 10.1097/MIB.0000000000000761] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
60 Matsuoka K, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K, Yoshimura N, Hibi T. Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Dig Dis Sci. 2018;63:1910-1919. [PMID: 29450747 DOI: 10.1007/s10620-018-4946-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
61 Borrego-sánchez A, Awad M, Sainz-díaz C. Molecular Modeling of Adsorption of 5-Aminosalicylic Acid in the Halloysite Nanotube. Minerals 2018;8:61. [DOI: 10.3390/min8020061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018;1:CD011450. [PMID: 29338066 DOI: 10.1002/14651858.CD011450.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
63 Ding X, Li D, Li M, Wang H, He Q, Wang Y, Yu H, Tian D, Yu Q. SLC26A3 (DRA) prevents TNF-alpha-induced barrier dysfunction and dextran sulfate sodium-induced acute colitis. Lab Invest 2018;98:462-76. [PMID: 29330471 DOI: 10.1038/s41374-017-0005-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
64 Ding X, Li D, Li M, Tian D, Yu H, Yu Q. Tumor necrosis factor-α acts reciprocally with solute carrier family 26, member 3, (downregulated-in-adenoma) and reduces its expression, leading to intestinal inflammation. Int J Mol Med 2018;41:1224-32. [PMID: 29286110 DOI: 10.3892/ijmm.2017.3347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
65 Furuzawa Carballeda J, Fonseca Camarillo G, Yamamoto-Furusho JK. Interleukin 27 is up-regulated in patients with active inflammatory bowel disease. Immunol Res 2016;64:901-7. [PMID: 27221243 DOI: 10.1007/s12026-016-8804-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
66 Schniers A, Anderssen E, Fenton CG, Goll R, Pasing Y, Paulssen RH, Florholmen J, Hansen T. The Proteome of Ulcerative Colitis in Colon Biopsies from Adults - Optimized Sample Preparation and Comparison with Healthy Controls. Proteomics Clin Appl 2017;11. [PMID: 28856821 DOI: 10.1002/prca.201700053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
67 Hood MM, Jedel S. Mindfulness-Based Interventions in Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2017;46:859-874. [PMID: 29173527 DOI: 10.1016/j.gtc.2017.08.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
68 Dhingra R, Kedia S, Mouli VP, Garg SK, Singh N, Bopanna S, Singla V, Choudhury BN, Verma P, Tiwari V, Gupta SD, Makharia G, Ahuja V. Evaluating clinical, dietary, and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic, and histological remission: Predicting relapse in ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:1698-705. [DOI: 10.1111/jgh.13770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
69 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
70 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
71 Okahara K, Nagata N, Shimada T, Joya A, Hayashida T, Gatanaga H, Oka S, Sakurai T, Uemura N, Akiyama J. Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis. PLoS One 2017;12:e0183951. [PMID: 28886066 DOI: 10.1371/journal.pone.0183951] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
72 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
73 Villanacci V, Antonelli E, Lanzarotto F, Bozzola A, Cadei M, Bassotti G. Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study. Sci Rep 2017;7:6839. [PMID: 28754920 DOI: 10.1038/s41598-017-07338-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
74 Whitehead SJ, Ford C, Gama RM, Ali A, Mckaig B, Waldron JL, Steed H, Brookes MJ. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol 2017;70:1049-56. [DOI: 10.1136/jclinpath-2017-204340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
75 Sagawa T, Kakizaki S, Tomizawa T, Nakayama T, Tanaka H, Tojima H, Sato K, Kusano M, Okamura S, Yamada M. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. Colorectal Dis 2016;18:696-702. [PMID: 26748553 DOI: 10.1111/codi.13258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
76 Ogata H, Ohori A, Nishino H, Mizushima S, Hagino A, Hibi T. Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study. Intest Res 2017;15:358-67. [PMID: 28670233 DOI: 10.5217/ir.2017.15.3.358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
77 Ogata H, Aoyama N, Mizushima S, Hagino A, Hibi T. Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. Intest Res 2017;15:368-79. [PMID: 28670234 DOI: 10.5217/ir.2017.15.3.368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
78 Kobayashi T, Matsuoka K, Yokoyama Y, Nakamura T, Ino T, Numata T, Shibata H, Aoki H, Matsuno Y, Hibi T. A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. J Gastroenterol 2018;53:387-96. [PMID: 28597225 DOI: 10.1007/s00535-017-1356-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
79 Khan MN, Lane ME, McCarron PA, Tambuwala MM. Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function. Inflammopharmacology 2018;26:561-9. [PMID: 28528363 DOI: 10.1007/s10787-017-0364-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
80 Kalappurayil NB, Thomas J, Mankuni B, Thomas V. Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis. J Clin Diagn Res 2017;11:EC07-11. [PMID: 28511386 DOI: 10.7860/JCDR/2017/22816.9332] [Reference Citation Analysis]
81 Kedia S, Bhatia V, Thareja S, Garg S, Mouli VP, Bopanna S, Tiwari V, Makharia G, Ahuja V. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther 2017; 8(2): 147-154 [PMID: 28533925 DOI: 10.4292/wjgpt.v8.i2.147] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
82 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
83 Heidarian F, Noormohammadi Z, Asadzadeh Aghdaei H, Alebouyeh M. Relative Abundance of Streptococcus spp. and its Association with Disease Activity in Inflammatory Bowel Disease Patients Compared with Controls. Arch Clin Infect Dis 2017;In Press. [DOI: 10.5812/archcid.57291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
84 Zhao X, Zhou C, Ma J, Zhu Y, Sun M, Wang P, Zhang Y, Ma H, Zhang H. Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. Sci Rep 2017;7:46693. [PMID: 28440311 DOI: 10.1038/srep46693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 Nagahori M, Kochi S, Hanai H, Yamamoto T, Nakamura S, Omuro S, Watanabe M, Hibi T; OPTIMUM Study Group. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol 2017;17:47. [PMID: 28390410 DOI: 10.1186/s12876-017-0604-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
86 Tsuchiya K, Ikeda T, Batmunkh B, Choijookhuu N, Ishizaki H, Hotokezaka M, Hishikawa Y, Nanashima A. Frequency of CD4+CD161+ T Cell and Interleukin-10 Expression in Inflammatory Bowel Diseases. Acta Histochem Cytochem 2017;50:21-8. [PMID: 28386147 DOI: 10.1267/ahc.16035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
87 Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801-813. [PMID: 28112419 DOI: 10.1111/apt.13948] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 13.4] [Reference Citation Analysis]
88 Kawakami A, Tanaka M, Ochiai R, Naganuma M, Kunisaki R, Kazuma K. Difficulties in Performing Mesalazine Enemas and Factors Related to Discontinuation Among Patients With Ulcerative Colitis: . Gastroenterology Nursing 2017;40:101-8. [DOI: 10.1097/sga.0000000000000147] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
89 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
90 Neilson K, Ftanou M, Monshat K, Salzberg M, Bell S, Kamm MA, Connell W, Knowles SR, Sevar K, Mancuso SG, Castle D. A Controlled Study of a Group Mindfulness Intervention for Individuals Living With Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:694-701. [PMID: 26529560 DOI: 10.1097/MIB.0000000000000629] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
91 Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. J Clin Gastroenterol 2016;50:318-25. [PMID: 26368296 DOI: 10.1097/MCG.0000000000000414] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
92 Manguso F, Bennato R, Lombardi G, Riccio E, Costantino G, Fries W. Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166455. [PMID: 27846307 DOI: 10.1371/journal.pone.0166455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
93 Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol 2016; 22(42): 9324-9332 [PMID: 27895420 DOI: 10.3748/wjg.v22.i42.9324] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
94 Fangbin Z, Xiang G, Liang D, Hui L, Xueding W, Baili C, Huichang B, Yinglian X, Peng C, Lizi Z. Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study (Baltimore). Medicine. 2016;95:e3326. [PMID: 27082580 DOI: 10.1097/md.0000000000003326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
95 Fitzgerald JM, Marsh TD. Mesalamine in Ulcerative Colitis. DICP 1991;25:140-5. [DOI: 10.1177/106002809102500208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
96 Connelly TM, Devane L, Kelly JC, Wrafter P, Messaris E. The 100 classic papers in ulcerative colitis: a bibliometric analysis. Expert Rev Gastroenterol Hepatol 2016;10:1187-95. [PMID: 27531253 DOI: 10.1080/17474124.2016.1216786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
97 Zhao X, Li N, Ren Y, Ma T, Wang C, Wang J, You S. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160500. [PMID: 27501314 DOI: 10.1371/journal.pone.0160500] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
98 Tian T, Zhou Y, Feng X, Ye S, Wang H, Wu W, Tan W, Yu C, Hu J, Zheng R, Chen Z, Pei X, Luo H. MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting. Sci Rep 2016;6:30824. [PMID: 27476546 DOI: 10.1038/srep30824] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
99 Kucharski M, Karczewski J, Mańkowska-wierzbicka D, Karmelita-katulska K, Grzymisławski M, Kaczmarek E, Iwanik K, Rzymski P, Swora-cwynar E, Linke K, Dobrowolska A. Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2016;28:722-30. [DOI: 10.1097/meg.0000000000000601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
100 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply. Aliment Pharmacol Ther 2016;43:1243. [PMID: 27137731 DOI: 10.1111/apt.13602] [Reference Citation Analysis]
101 Laharie D, Poullenot F. Letter: which patient profile for tacrolimus in ulcerative colitis? Aliment Pharmacol Ther 2016;43:1242-3. [PMID: 27137730 DOI: 10.1111/apt.13598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
102 Bruckstein AH. New salicylate therapies for ulcerative colitis. Postgraduate Medicine 2016;88:79-89. [DOI: 10.1080/00325481.1990.11704726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Kolho K. Assessment of disease activity in pediatric ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2016;10:1127-34. [DOI: 10.1080/17474124.2016.1185364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
104 Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
105 Zhang P, Liu X, Guo A, Xiong J, Fu Y, Zou K. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease. Dig Dis Sci 2016;61:2608-18. [DOI: 10.1007/s10620-016-4136-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
106 Cohen RD, Dalal SR. Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. Inflamm Bowel Dis. 2015;21:1719-1736. [PMID: 26020604 DOI: 10.1097/mib.0000000000000379] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
107 Sun J, Yuan Y. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. Adv Ther 2016;33:410-22. [PMID: 26905266 DOI: 10.1007/s12325-016-0304-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
108 Sun J, Yuan Y. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. Adv Ther 2016;33:400-9. [PMID: 26898569 DOI: 10.1007/s12325-016-0303-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
109 Zakko SF, Gordon GL, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP, Lichtenstein GR. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. Postgrad Med. 2016;128:273-281. [PMID: 26861051 DOI: 10.1080/00325481.2016.1152876] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
110 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 220] [Cited by in F6Publishing: 191] [Article Influence: 36.7] [Reference Citation Analysis]
111 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
112 Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 2016;10:786-94. [PMID: 26874351 DOI: 10.1093/ecco-jcc/jjw044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
113 Suzuki Y, Uchiyama K, Kato M, Matsuo K, Nakagawa T, Kishikawa H, Kimura N, Kasanuki J, Ino S. Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation. J Clin Gastroenterol 2015;49:401-6. [PMID: 25127112 DOI: 10.1097/MCG.0000000000000199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
114 Edfors K, Ståhlberg D, Söderman C. Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease. Ther Apher Dial 2016;20:79-85. [PMID: 26841133 DOI: 10.1111/1744-9987.12336] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
115 Sawada K, Ohdo M, Ino T, Nakamura T, Numata T, Shibata H, Sakou J, Kusada M, Hibi T. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study. Ther Apher Dial. 2016;20:197-204. [PMID: 26771066 DOI: 10.1111/1744-9987.12357] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
116 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: A retrospective observational study. Aliment Pharmacol Ther. 2016;43:705-716. [PMID: 26762838 DOI: 10.1111/apt.13531] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
117 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
118 Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016;10:607-618. [PMID: 26746169 DOI: 10.1093/ecco-jcc/jjw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
119 Shi HY, Chan FK, Tsang SW, Hui YT, Sze SF, Ching JY, Chung T, Iu CY, Lo FH, Shan EH, Li MK, Wu JC, Sung JJ, Ng SC. Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2015;21:840-6. [PMID: 25738375 DOI: 10.1097/MIB.0000000000000334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
120 Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016;10:286-295. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
121 Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, Bortey E, Paterson C, Forbes WP. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Dig Dis Sci. 2016;61:221-229. [PMID: 26563167 DOI: 10.1007/s10620-015-3866-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
122 Kini AT, Thangaraj KR, Simon E, Shivappagowdar A, Thiagarajan D, Abbas S, Ramachandran A, Venkatraman A. Aberrant Niche Signaling in the Etiopathogenesis of Ulcerative Colitis: . Inflammatory Bowel Diseases 2015;21:2549-61. [DOI: 10.1097/mib.0000000000000523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
123 Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
124 Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci 2015;60:3408-17. [PMID: 26386854 DOI: 10.1007/s10620-015-3868-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
125 Halloran B, Chang J, Shih DQ, McGovern D, Famulski K, Evaschesen C, Fedorak RN, Thiesen A, Targan S, Halloran PF. Molecular patterns in human ulcerative colitis and correlation with response to infliximab. Inflamm Bowel Dis 2014;20:2353-63. [PMID: 25397893 DOI: 10.1097/MIB.0000000000000239] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
126 Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther 2015;42:549-58. [PMID: 26140337 DOI: 10.1111/apt.13308] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
127 Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine 2015;75:389-402. [PMID: 26141420 DOI: 10.1016/j.cyto.2015.04.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
128 Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:846-852. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
129 Lichtenstein GR, Barrett AC, Bortey E, Paterson C, Forbes WP. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis. Inflamm Bowel Dis 2014;20:1399-406. [PMID: 24874460 DOI: 10.1097/MIB.0000000000000076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
130 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 24.6] [Reference Citation Analysis]
131 Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014;28:325-9. [PMID: 24945187 DOI: 10.1155/2014/737349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
132 Ruemmele FM, Hyams JS, Otley A, Griffiths A, Kolho KL, Dias JA, Levine A, Escher JC, Taminiau J, Veres G, Colombel JF, Vermeire S, Wilson DC, Turner D. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 2015;64:438-46. [PMID: 24821616 DOI: 10.1136/gutjnl-2014-307008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 7.6] [Reference Citation Analysis]
133 Carter D, Eliakim R. Current role of endoscopy in inflammatory bowel disease diagnosis and management. Curr Opin Gastroenterol. 2014;30:370-377. [PMID: 24837226 DOI: 10.1097/mog.0000000000000074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
134 Maeda Y, Ohtsuka K, Kudo SE, Wakamura K, Mori Y, Ogata N, Wada Y, Misawa M, Yamauchi A, Hayashi S, Kudo T, Hayashi T, Miyachi H, Yamamura F, Ishida F, Inoue H, Hamatani S. Endocytoscopic narrow-band imaging efficiency for evaluation of inflammatory activity in ulcerative colitis. World J Gastroenterol 2015; 21(7): 2108-2115 [PMID: 25717245 DOI: 10.3748/wjg.v21.i7.2108] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
135 Spekhorst LM, Visschedijk MC, Alberts R, Festen EA, van der Wouden EJ, Dijkstra G, (ICC) RKWDIOCAC. Performance of the Montreal classification for inflammatory bowel diseases. World J Gastroenterol 2014; 20(41): 15374-15381 [PMID: 25386087 DOI: 10.3748/wjg.v20.i41.15374] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
136 Chen L, Wang W, Zhou R, Ng SC, Li J, Huang M, Zhou F, Wang X, Shen B, A Kamm M, Wu K, Xia B. Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. Medicine (Baltimore) 2014;93:e51. [PMID: 25121355 DOI: 10.1097/MD.0000000000000051] [Cited by in Crossref: 90] [Cited by in F6Publishing: 59] [Article Influence: 11.3] [Reference Citation Analysis]
137 Boschetti G, Nancey S, Moussata D, Stefanescu C, Roblin X, Chauvenet M, Stroeymeyt K, Bouhnik Y, Flourié B. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. Digestive and Liver Disease 2014;46:875-80. [DOI: 10.1016/j.dld.2014.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
138 Yarlas A, Yen L, Hodgkins P. The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine. Qual Life Res 2015;24:671-83. [PMID: 25193617 DOI: 10.1007/s11136-014-0797-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
139 Clemente A, Arques MDC. Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents. World J Gastroenterol 2014; 20(30): 10305-10315 [PMID: 25132747 DOI: 10.3748/wjg.v20.i30.10305] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
140 Kim JW, Kim HJ, Lee CK, Shim JJ, Jang JY, Dong SH, Kim BH, Chang YW, Chi SG. Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. Dig Dis Sci 2014;59:2947-57. [PMID: 25052149 DOI: 10.1007/s10620-014-3282-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
141 Walsh A, Palmer R, Travis S. Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. Gastrointestinal Endoscopy Clinics of North America 2014;24:367-78. [DOI: 10.1016/j.giec.2014.03.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 8.6] [Reference Citation Analysis]
142 Shi HY, Ng SC, Tsoi KK, Wu JC, Sung JJ, Chan FK. The role of capsule endoscopy in assessing mucosal inflammation in ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:47-54. [PMID: 24966092 DOI: 10.1586/17474124.2014.934359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
143 Kobayashi K, Hirai F, Naganuma M, Watanabe K, Ando T, Nakase H, Matsuoka K, Watanabe M. A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings. J Crohns Colitis 2014;8:1444-53. [PMID: 24923656 DOI: 10.1016/j.crohns.2014.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
144 Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
145 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
146 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
147 Managlia E, Katzman RB, Brown JB, Barrett TA. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflamm Bowel Dis. 2013;19:2051-2060. [PMID: 23867870 DOI: 10.1097/mib.0b013e318297d741] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
148 Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63:433-41. [PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258] [Cited by in Crossref: 167] [Cited by in F6Publishing: 141] [Article Influence: 20.9] [Reference Citation Analysis]
149 Yokoyama Y, Matsuoka K, Kobayashi T, Sawada K, Fujiyoshi T, Ando T, Ohnishi Y, Ishida T, Oka M, Yamada M, Nakamura T, Ino T, Numata T, Aoki H, Sakou J, Kusada M, Maekawa T, Hibi T. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. J Crohns Colitis. 2014;8:981-991. [PMID: 24556083 DOI: 10.1016/j.crohns.2014.01.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
150 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
151 Fiorino G, Gilardi D, Naccarato P, Sociale OR, Danese S. Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. Dig Liver Dis 2014;46:330-4. [PMID: 24462118 DOI: 10.1016/j.dld.2013.12.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
152 Lawlor G, Ahmed A, Moss AC. Once-daily mesalamine granules for ulcerative colitis. Expert Review of Clinical Immunology 2014;6:521-6. [DOI: 10.1586/eci.10.22] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
153 Schreiber S, Kamm MA, Lichtenstein GR. Mesalamine with MMX™ technology for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:299-314. [DOI: 10.1586/17474124.2.3.299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
154 Hirai F, Takatsu N, Yano Y, Satou Y, Takahashi H, Ishikawa S, Tsurumi K, Hisabe T, Matsui T. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus: CYP3A5 gene and ulcerative colitis. J Gastroenterol Hepatol 2014;29:60-6. [DOI: 10.1111/jgh.12361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
155 Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29:485-491. [PMID: 24343276 DOI: 10.1007/s00384-013-1817-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
156 Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv and Transl Res 2014;4:187-202. [DOI: 10.1007/s13346-013-0185-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
157 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 410] [Article Influence: 54.0] [Reference Citation Analysis]
158 Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014;46:135-139. [PMID: 24246151 DOI: 10.1016/j.dld.2013.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
159 Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, Wang G, Xia B. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014;52:398-406. [PMID: 24478468 DOI: 10.1128/jcm.01500-13] [Cited by in Crossref: 198] [Cited by in F6Publishing: 137] [Article Influence: 22.0] [Reference Citation Analysis]
160 Lemmens B, Arijs I, Van Assche G, Sagaert X, Geboes K, Ferrante M, Rutgeerts P, Vermeire S, De Hertogh G. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis. 2013;19:1194-1201. [PMID: 23518809 DOI: 10.1097/mib.0b013e318280e75f] [Cited by in Crossref: 92] [Cited by in F6Publishing: 40] [Article Influence: 10.2] [Reference Citation Analysis]
161 Wolff S, Terheggen G, Mueller R, Greinwald R, Franklin J, Kruis W. Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?: . Inflammatory Bowel Diseases 2013;19:2611-5. [DOI: 10.1097/01.mib.0000437044.43961.00] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
162 Furuzawa-Carballeda J, Fonseca-Camarillo G, Lima G, Yamamoto-Furusho JK. Indoleamine 2,3-dioxygenase: expressing cells in inflammatory bowel disease-a cross-sectional study. Clin Dev Immunol 2013;2013:278035. [PMID: 24282429 DOI: 10.1155/2013/278035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
163 Masoodi M, Pearl DS, Eiden M, Shute JK, Brown JF, Calder PC, Trebble TM. Altered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiology. PLoS One 2013;8:e76532. [PMID: 24204637 DOI: 10.1371/journal.pone.0076532] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
164 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
165 Zhao Y, Zhao X, Bing Y, Pan J, Li X. Syntheses, Crystal Structures and Electrochemical Activities of Co(II) and Cu(II)-Complexes with 5-Aminosalicylate Derivatives. J Chem Crystallogr 2013;43:568-75. [DOI: 10.1007/s10870-013-0462-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
166 Singla V, Pratap Mouli V, Garg SK, Rai T, Choudhury BN, Verma P, Deb R, Tiwari V, Rohatgi S, Dhingra R. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis. 2014;8:208-214. [PMID: 24011514 DOI: 10.1016/j.crohns.2013.08.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
167 Berkowitz D, Peri R, Lavy A, Kessel A. Increased Toll-like receptor 9 expression by B cells from inflammatory bowel disease patients. Hum Immunol. 2013;74:1519-1523. [PMID: 24007656 DOI: 10.1016/j.humimm.2013.08.285] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
168 Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1186/1471-230x-13-130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
169 Hodgkins P, Yen L, Yarlas A, Karlstadt R, Solomon D, Kane S. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis. Inflamm Bowel Dis 2013;19:386-96. [PMID: 22648999 DOI: 10.1002/ibd.23022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
170 Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1016/s1873-9946(13)60351-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
171 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
172 Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-221. [PMID: 23340060 DOI: 10.1097/mcg.0b013e3182732ff5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
173 Husain N, Tokoro K, Popov JM, Naides SJ, Kwasny MJ, Buchman AL. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis. J Clin Gastroenterol. 2013;47:246-251. [PMID: 23269308 DOI: 10.1097/mcg.0b013e3182582cdb] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
174 Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study. Aliment Pharmacol Ther. 2013;38:264-273. [PMID: 23734840 DOI: 10.1111/apt.12362] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
175 Rubin DT. What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis. Gastroenterology 2013;145:45-7. [PMID: 23726879 DOI: 10.1053/j.gastro.2013.05.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
176 Pearl DS, Masoodi M, Eiden M, Brümmer J, Gullick D, McKeever TM, Whittaker MA, Nitch-Smith H, Brown JF, Shute JK. Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. J Crohns Colitis. 2014;8:70-79. [PMID: 23619007 DOI: 10.1016/j.crohns.2013.03.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
177 Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol 2013;2013:304894. [PMID: 23691335 DOI: 10.1155/2013/304894] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
178 Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV Jr, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-157. e2. [PMID: 23528626 DOI: 10.1053/j.gastro.2013.03.025] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 15.6] [Reference Citation Analysis]
179 Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D; MOTUS study investigators. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013;37:767-75. [PMID: 23451806 DOI: 10.1111/apt.12266] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
180 Feng X, Wang H, Ye S, Guan J, Tan W, Cheng S, Wei G, Wu W, Wu F, Zhou Y. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PLoS One. 2012;7:e52782. [PMID: 23285182 DOI: 10.1371/journal.pone.0052782] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 7.9] [Reference Citation Analysis]
181 Shah SA, Peppercorn MA. A Comparative Review of Topical Therapies for Inflammatory Bowel Disease. Clin Immunother 1996;6:117-29. [DOI: 10.1007/bf03259508] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
182 Dhanda AD, Creed TJ, Greenwood R, Sands BE, Probert CS. Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?: . Inflammatory Bowel Diseases 2012;18:2056-62. [DOI: 10.1002/ibd.22879] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
183 Freeman HJ. Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. Clin Med Insights Gastroenterol 2012;5:77-83. [PMID: 24833937 DOI: 10.4137/CGast.S8673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Barreiro-de Acosta M, Lorenzo A, Mera J, Dominguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009;3:271-6. [PMID: 21172286 DOI: 10.1016/j.crohns.2009.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
185 Pearl DS, Shah K, Whittaker MA, Nitch-Smith H, Brown JF, Shute JK, Trebble TM. Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity. J Crohns Colitis. 2013;7:481-489. [PMID: 22974822 DOI: 10.1016/j.crohns.2012.07.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
186 Feagan BG, Macdonald JK. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis: . Inflammatory Bowel Diseases 2012;18:1785-94. [DOI: 10.1002/ibd.23024] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
187 Kruis W, Leifeld L, Morgenstern J, Pfützer R, Reimers B, Ceplis-Kastner S; CARE study group. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study. J Crohns Colitis 2013;7:e125-32. [PMID: 22951030 DOI: 10.1016/j.crohns.2012.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
188 Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol. 2012;47:538-547. [PMID: 22486187 DOI: 10.3109/00365521.2012.667146] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
189 Chan G, Fefferman DS, Farrell RJ. Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy. Gastroenterol Clin North Am 2012;41:271-90. [PMID: 22500517 DOI: 10.1016/j.gtc.2012.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
190 Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218-1226.e1-2. [PMID: 22892337 DOI: 10.1053/j.gastro.2012.08.003] [Cited by in Crossref: 148] [Cited by in F6Publishing: 134] [Article Influence: 14.8] [Reference Citation Analysis]
191 D'haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis. American Journal of Gastroenterology 2012;107:1064-77. [DOI: 10.1038/ajg.2012.103] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
192 Rameshshanker R, Arebi N. Endoscopy in inflammatory bowel disease when and why. World J Gastrointest Endosc 2012; 4(6): 201-211 [PMID: 22720120 DOI: 10.4253/wjge.v4.i6.201] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
193 Solomon D, Yarlas A, Hodgkins P, Karlstadt R, Yen L, Kane S. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Aliment Pharmacol Ther 2012;35:1386-96. [PMID: 22536781 DOI: 10.1111/j.1365-2036.2012.05107.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
194 Sakuraba A, Sato T, Morohoshi Y, Matsuoka K, Okamoto S, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study. Ther Apher Dial. 2012;16:213-218. [PMID: 22607563 DOI: 10.1111/j.1744-9987.2012.01064.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
195 Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42. [PMID: 21997563 DOI: 10.1136/gutjnl-2011-300486] [Cited by in Crossref: 322] [Cited by in F6Publishing: 283] [Article Influence: 32.2] [Reference Citation Analysis]
196 Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
197 Krier M, Kaltenbach T, McQuaid K, Soetikno R. Potential use of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol. 2011;106:2063-2067. [PMID: 22138934 DOI: 10.1038/ajg.2011.329] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
198 Chaparro M. [Advances in the management of ulcerative colitis presented at Digestive Disease Week 2011]. Gastroenterol Hepatol 2011;34 Suppl 2:52-9. [PMID: 22330157 DOI: 10.1016/S0210-5705(11)70021-8] [Reference Citation Analysis]
199 Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012;6:750-5. [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
200 Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, Issa M. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr 2011;35:308-16. [PMID: 21527593 DOI: 10.1177/0148607110381267] [Cited by in Crossref: 199] [Cited by in F6Publishing: 188] [Article Influence: 18.1] [Reference Citation Analysis]
201 Di Sabatino A, Biancheri P, Rovedatti L, Macdonald TT, Corazza GR. Recent advances in understanding ulcerative colitis. Intern Emerg Med. 2012;7:103-111. [PMID: 22068230 DOI: 10.1007/s11739-011-0719-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
202 Higurashi T, Endo H, Yoneda M, Hosono K, Sakai E, Takahashi H, Inamori M, Uchiyama S, Kojima T, Kawana K. Capsule-endoscopic findings of ulcerative colitis patients. Digestion. 2011;84:306-314. [PMID: 22041924 DOI: 10.1159/000333086] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
203 Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011;56:633-640. [PMID: 21945121 DOI: 10.1016/j.cyto.2011.08.036] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 8.2] [Reference Citation Analysis]
204 Mikhailova TL, Sishkova E, Poniewierka E, Zhidkov KP, Bakulin IG, Kupcinskas L, Lesniakowski K, Grinevich VB, Malecka-Panas E, Ardizzone S, D'Arienzo A, Valpiani D, Koch M, Denapiene G, Vago G, Fociani P, Zerbi P, Ceracchi M, Camerini R, Gasbarrini G. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther 2011;34:1088-97. [PMID: 21929562 DOI: 10.1111/j.1365-2036.2011.04844.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
205 Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011;34:747-756. [PMID: 21848857 DOI: 10.1111/j.1365-2036.2011.04800.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
206 Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol 2011;46:1003-9. [PMID: 21681409 DOI: 10.1007/s00535-011-0428-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
207 Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042-1047. [PMID: 21674732 DOI: 10.1002/ibd.21800] [Cited by in Crossref: 116] [Cited by in F6Publishing: 99] [Article Influence: 10.5] [Reference Citation Analysis]
208 Terai T, Sugimoto M, Osawa S, Sugimoto K, Furuta T, Kanaoka S, Ikuma M. Successful treatment of ulcerative colitis complicated by Sweet’s syndrome by corticosteroid therapy and leukocytapheresis. Clin J Gastroenterol 2011;4:151-6. [DOI: 10.1007/s12328-011-0215-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
209 Travis SPL, Higgins PDR, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’haens G. Review article: defining remission in ulcerative colitis: Review: remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2011;34:113-24. [DOI: 10.1111/j.1365-2036.2011.04701.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 10.9] [Reference Citation Analysis]
210 Navaneethan U, Shen L, Venkatesh PG, Hammel J, Patel V, Remzi FH, Kiran RP. Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients. J Crohns Colitis. 2011;5:415-422. [PMID: 21939915 DOI: 10.1016/j.crohns.2011.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
211 Yamamoto T, Umegae S, Matsumoto K. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy. Digestive and Liver Disease 2011;43:386-90. [DOI: 10.1016/j.dld.2010.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
212 Savchenko AS, Inoue A, Ohashi R, Jiang S, Hasegawa G, Tanaka T, Hamakubo T, Kodama T, Aoyagi Y, Ushiki T, Naito M. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol Int. 2011;61:290-297. [PMID: 21501295 DOI: 10.1111/j.1440-1827.2011.02651.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
213 Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011;33:996-1009. [PMID: 21385194 DOI: 10.1111/j.1365-2036.2011.04619.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
214 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
215 Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010;16:1947-1956. [PMID: 20310020 DOI: 10.1002/ibd.21258] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
216 Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16:1905-1911. [PMID: 20310015 DOI: 10.1002/ibd.21260] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
217 Shiomi Y, Nishiumi S, Ooi M, Hatano N, Shinohara M, Yoshie T, Kondo Y, Furumatsu K, Shiomi H, Kutsumi H. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis. 2011;17:2261-2274. [PMID: 21287666 DOI: 10.1002/ibd.21616] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 7.3] [Reference Citation Analysis]
218 Florholmen J, Øverland G, Olsen T, Rismo R, Cui G, Christiansen I, Paulssen EJ, Goll R. Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis. Ulcers 2011;2011:1-7. [DOI: 10.1155/2011/156407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
219 Ito H, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T, Takano Y, Hibi T. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16:1567-1574. [PMID: 20049950 DOI: 10.1002/ibd.21193] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
220 Ito H, Iida M, Matsumoto T, Suzuki Y, Aida Y, Yoshida T, Takano Y, Hibi T. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis 2010;16:1575-82. [PMID: 20049949 DOI: 10.1002/ibd.21194] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
221 Kao J, Kwok K, Das KM. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. J Clin Gastroenterol 2010;44:531-5. [PMID: 20495466 DOI: 10.1097/MCG.0b013e3181db1a61] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
222 Sponheim J, Pollheimer J, Olsen T, Balogh J, Hammarström C, Loos T, Kasprzycka M, Sørensen DR, Nilsen HR, Küchler AM. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol. 2010;177:2804-2815. [PMID: 21037074 DOI: 10.2353/ajpath.2010.100378] [Cited by in Crossref: 105] [Cited by in F6Publishing: 106] [Article Influence: 8.8] [Reference Citation Analysis]
223 Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;:CD007698. [PMID: 20927762 DOI: 10.1002/14651858.CD007698.pub2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
224 Hiwatashi N, Suzuki Y, Mitsuyama K, Munakata A, Hibi T. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol. 2011;46:46-56. [PMID: 20878425 DOI: 10.1007/s00535-010-0308-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
225 Vidali F, Di Sabatino A, Broglia F, Cazzola P, Biancheri P, Viera FT, Vanoli A, Alvisi C, Perego M, Corazza GR. Increased CD8+ intraepithelial lymphocyte infiltration and reduced surface area to volume ratio in the duodenum of patients with ulcerative colitis. Scand J Gastroenterol. 2010;45:684-689. [PMID: 20201621 DOI: 10.3109/00365521003663662] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
226 Sonu I, Lin MV, Blonski W, Lichtenstein GR. Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2010;39:559-99. [DOI: 10.1016/j.gtc.2010.08.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
227 Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Merchant K, Shaw A, Bortey E, Forbes WP. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Aliment Pharmacol Ther. 2010;32:990-999. [PMID: 20937044 DOI: 10.1111/j.1365-2036.2010.04438.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
228 Nakase H, Fujiyama Y, Oshitani N, Oga T, Nonomura K, Matsuoka T, Esaki Y, Murayama T, Teramukai S, Chiba T, Narumiya S. Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. Inflamm Bowel Dis. 2010;16:731-733. [PMID: 19760781 DOI: 10.1002/ibd.21080] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
229 Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011;56:513-22. [PMID: 20676771 DOI: 10.1007/s10620-010-1334-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
230 Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
231 Whitlow CB. Ulcerative proctitis. Clin Colon Rectal Surg 2004;17:21-7. [PMID: 20011281 DOI: 10.1055/s-2004-823067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
232 Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004;17:7-19. [PMID: 20011280 DOI: 10.1055/s-2004-823066] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
233 Hartmann F, Stein J. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010;32:368-376. [PMID: 20491741 DOI: 10.1111/j.1365-2036.2010.04354.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
234 Takahashi M, Katayama Y, Suzuki K, Koizumi K, Nishida K, Kuwayama H. Does colonoscopy by a skilled endoscopist cause any adverse effects in quiescent ulcerative colitis patients? a case-control study. J Clin Gastroenterol 2010;44:720-2. [PMID: 20421809 DOI: 10.1097/MCG.0b013e3181d7b1be] [Reference Citation Analysis]
235 Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, Kanai T, Ogata H, Iwao Y, Hibi T. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010;45:936-43. [DOI: 10.1007/s00535-010-0244-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
236 Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010;10:13. [PMID: 20398311 DOI: 10.1186/1472-6882-10-13] [Cited by in Crossref: 122] [Cited by in F6Publishing: 109] [Article Influence: 10.2] [Reference Citation Analysis]
237 Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-346. [PMID: 19637362 DOI: 10.1002/ibd.20997] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 12.5] [Reference Citation Analysis]
238 Hirai F, Matsui T, Aoyagi K, Inoue N, Hibi T, Oshitani N, Fujii H, Kobayashi K, Suzuki Y, Tanaka S. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc. 2010;22:39-44. [PMID: 20078663 DOI: 10.1111/j.1443-1661.2009.00916.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
239 Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol 2009;21:558-64. [PMID: 19194304 DOI: 10.1097/MEG.0b013e328326cacb] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
240 Quiros JA, Heyman MB, Pohl JF, Attard TM, Pieniaszek HJ, Bortey E, Walker K, Forbes WP. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J Pediatr Gastroenterol Nutr 2009;49:571-9. [PMID: 19633577 DOI: 10.1097/MPG.0b013e31819bcac4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
241 Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;20:CD004115. [PMID: 20091560 DOI: 10.1002/14651858.cd004115.pub2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
242 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
243 Freeman HJ. Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol 2010; 16(1): 15-20 [PMID: 20039444 DOI: 10.3748/wjg.v16.i1.15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
244 Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis. 2010;4:275-282. [PMID: 21122516 DOI: 10.1016/j.crohns.2009.11.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
245 Pineton de Chambrun G, Peyrin-biroulet L, Lémann M, Colombel J. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29. [DOI: 10.1038/nrgastro.2009.203] [Cited by in Crossref: 321] [Cited by in F6Publishing: 302] [Article Influence: 24.7] [Reference Citation Analysis]
246 Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009;44:727-735. [PMID: 19294580 DOI: 10.1080/00365520902803507] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
247 Bolin TD, Wong S, Crouch R, Engelman JL, Riordan SM. Appendicectomy as a therapy for ulcerative proctitis. Am J Gastroenterol 2009;104:2476-82. [PMID: 19584834 DOI: 10.1038/ajg.2009.388] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
248 Zhang Z, Kennedy H. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol. 2009;21:1-8. [PMID: 19011573 DOI: 10.1097/MEG.0b013e32830bfb88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
249 Caprilli R, Cesarini M, Angelucci E, Frieri G. The long journey of salicylates in ulcerative colitis: The past and the future. Journal of Crohn's and Colitis 2009;3:149-56. [DOI: 10.1016/j.crohns.2009.05.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
250 Meucci G, D'Incà R, Maieron R, Orzes N, Vecchi M, Visentini D, Minoli G, Dal Pont E, Zilli M, Benedetti E. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. Dig Liver Dis. 2010;42:191-195. [PMID: 19695969 DOI: 10.1016/j.dld.2009.07.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
251 Kanmura S, Uto H, Numata M, Hashimoto S, Moriuchi A, Fujita H, Oketani M, Ido A, Kodama M, Ohi H. Human neutrophil peptides 1-3 are useful biomarkers in patients with active ulcerative colitis. Inflamm Bowel Dis. 2009;15:909-917. [PMID: 19107772 DOI: 10.1002/ibd.20854] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
252 Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, Peracchi M, Bardella MT, Piodi L. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:867-871. [PMID: 19090560 DOI: 10.1002/ibd.20851] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
253 Mulder CJJ, Tytgat GNJ, Wiltink EHH, Houthoff H. Comparison of 5-Aminosalicylic Acid (3 g) and Prednisolone Phosphate Sodium Enemas (30 mg) in the Treatment of Distal Ulcerative Colitis: A Prospective, Randomized, Double-Blind Trial. Scandinavian Journal of Gastroenterology 2009;23:1005-8. [DOI: 10.3109/00365528809090161] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
254 Jacobsen BA, Abildgaard K, Rasmussen HH, Christensen LA, Fallingborg J, Hansen SH, Rasmussen SN. Availability of Mesalazine (5-Aminosalicylic Acid) from Enemas and Suppositories during Steady-State Conditions. Scandinavian Journal of Gastroenterology 2009;26:374-8. [DOI: 10.3109/00365529108996497] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
255 S.-w. Han, E. Mccoll, N. Steen, J.. The Inflammatory Bowel Disease Questionnaire: A Valid and Reliable Measure in Ulcerative Colitis Patients in the North East of England. Scandinavian Journal of Gastroenterology 2009;33:961-6. [DOI: 10.1080/003655298750026994] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
256 Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scandinavian Journal of Gastroenterology 2009;42:1306-11. [DOI: 10.1080/00365520701396091] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
257 Riley SA, Gupta I, Mani V. A Comparison of Sucralfate and Prednisolone Enemas in the Treatment of Active Distal Ulcerative Colitis. Scandinavian Journal of Gastroenterology 2009;24:1014-8. [DOI: 10.3109/00365528909089249] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
258 Campieri M, De Franchis R, Porro GB, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-Aminosalicylic Acid) Suppositories in the Treatment of Ulcerative Proctitis or Distal Proctosigmoiditis: A Randomized Controlled Trial. Scandinavian Journal of Gastroenterology 2009;25:663-8. [DOI: 10.3109/00365529008997590] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
259 Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Petronelli A, Miglioli M, Barbara L. Role of Rectal Formulations: Enemas. Scandinavian Journal of Gastroenterology 2009;25:63-5. [DOI: 10.3109/00365529009091914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
260 Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081-1088. [PMID: 19577010 DOI: 10.1016/j.cgh.2009.06.024] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 9.3] [Reference Citation Analysis]
261 Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H. Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2009;7:762-9. [DOI: 10.1016/j.cgh.2009.04.004] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 7.2] [Reference Citation Analysis]
262 Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1-8. [PMID: 18671232 DOI: 10.1002/ibd.20580] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
263 Kalyoncu D, Urganci N, Calis AB, Ozbal A. Sensorineural hearing loss in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2010;55:150-2. [PMID: 19255853 DOI: 10.1007/s10620-009-0714-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
264 Tindall WN. New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. American Journal of Health-System Pharmacy 2009;66:451-7. [DOI: 10.2146/ajhp070442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
265 Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R; International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58:233-40. [PMID: 18832520 DOI: 10.1136/gut.2008.154302] [Cited by in Crossref: 131] [Cited by in F6Publishing: 122] [Article Influence: 10.1] [Reference Citation Analysis]
266 Scaldaferri F, Sans M, Vetrano S, Correale C, Arena V, Pagano N, Rando G, Romeo F, Potenza AE, Repici A, Malesci A, Danese S. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009;39:290-300. [DOI: 10.1002/eji.200838316] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
267 Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, Lémann M. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008;103:3106-14. [PMID: 19086960 DOI: 10.1111/j.1572-0241.2008.02152.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
268 Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008;103:3115-22. [PMID: 19086961 DOI: 10.1111/j.1572-0241.2008.01743.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
269 Joyce JC, Waljee AK, Khan T, Wren PA, Dave M, Zimmermann EM, Wang S, Zhu J, Higgins PD. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health Qual Life Outcomes 2008;6:69. [PMID: 18803870 DOI: 10.1186/1477-7525-6-69] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
270 Hirata N, Oshitani N, Kamata N, Sogawa M, Yamagami H, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y, Maeda K, Hirakawa K, Arakawa T. Proliferation of immature plasma cells in pouchitis mucosa in patients with ulcerative colitis: . Inflammatory Bowel Diseases 2008;14:1084-90. [DOI: 10.1002/ibd.20447] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
271 Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;CD007216. [PMID: 18646177 DOI: 10.1002/14651858.cd007216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
272 Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902. [PMID: 18272546 DOI: 10.1136/gut.2007.138248] [Cited by in Crossref: 116] [Cited by in F6Publishing: 113] [Article Influence: 8.3] [Reference Citation Analysis]
273 Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause 2008;15:730-6. [DOI: 10.1097/gme.0b013e318159f190] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
274 Hirai F, Matsui T. A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. Clin J Gastroenterol 2008;1:40-5. [PMID: 26193460 DOI: 10.1007/s12328-008-0018-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
275 Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1440-1444. [PMID: 17852860 DOI: 10.1080/00365520701427094] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
276 Manguso F, Picascia S, Balzano A. Ulcerative colitis exacerbating after placement of intragastric balloon for the treatment of obesity: . Inflammatory Bowel Diseases 2008;14:872-3. [DOI: 10.1002/ibd.20373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
277 Soo I, Madsen KL, Tejpar Q, Sydora BC, Sherbaniuk R, Cinque B, Di Marzio L, Cifone MG, Desimone C, Fedorak RN. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol. 2008;22:237-242. [PMID: 18354751 DOI: 10.1155/2008/520383] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
278 Phelip JM, Ducros V, Faucheron JL, Flourie B, Roblin X. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:242-248. [PMID: 17941074 DOI: 10.1002/ibd.20309] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
279 Roblin X, Biroulet LP, Phelip JM, Nancey S, Flourie B. A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 × 10 8 Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease and Normal TPMT Activity. Am J Gastroenterology 2008;0:080428135811547-???. [DOI: 10.1111/j.1572-0241.2007.01743.x] [Reference Citation Analysis]
280 Florin THJ, Roberts RK, Watson MR, Radford-smith GL. Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Australian and New Zealand Journal of Medicine 1998;28:344-5. [DOI: 10.1111/j.1445-5994.1998.tb01960.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
281 Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 2008;27:1094-102. [PMID: 18363894 DOI: 10.1111/j.1365-2036.2008.03688.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
282 Yamamoto T, Maruyama Y, Umegae S, Matsumoto K, Saniabadi AR. Mucosal inflammation in the terminal ileum of ulcerative colitis patients: endoscopic findings and cytokine profiles. Dig Liver Dis. 2008;40:253-259. [PMID: 18243079 DOI: 10.1016/j.dld.2007.11.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
283 Flasar MH, Quezada S, Bijpuria P, Cross RK. Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study. Dig Dis Sci. 2008;53:2754-2760. [PMID: 18273704 DOI: 10.1007/s10620-007-0190-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
284 McCormack PL, Robinson DM, Perry CM. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis. Drugs 2007;67:2635-42. [PMID: 18034594 DOI: 10.2165/00003495-200767170-00010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
285 Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, Florholmen J. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42:1312-1320. [PMID: 17852866 DOI: 10.1080/00365520701409035] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
286 Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007;26:205-215. [PMID: 17593066 DOI: 10.1111/j.1365-2036.2007.03361.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 7.8] [Reference Citation Analysis]
287 Keefer L, Keshavarzian A. Feasibility and acceptability of gut-directed hypnosis on inflammatory bowel disease: a brief communication. Int J Clin Exp Hypn 2007;55:457-66. [PMID: 17786661 DOI: 10.1080/00207140701506565] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
288 Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008;53:875-91. [PMID: 17934839 DOI: 10.1007/s10620-007-9954-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
289 Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:21-29. [PMID: 17555418 DOI: 10.1111/j.1365-2036.2007.03349.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
290 Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V; ON BEHALF OF THE INTERNATIONAL SALOFALK FOAM STUDY GROUP. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis: CLINICAL TRIAL: LOW- VS. HIGH-VOLUME MESALAZINE FOAM FOR TREATMENT OF DISTAL UC. Alimentary Pharmacology & Therapeutics 2007;26:1237-49. [DOI: 10.1111/j.1365-2036.2007.03468.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
291 Dilger K, Trenk D, Rössle M, Cap M, Zähringer A, Wacheck V, Remmler C, Cascorbi I, Kreisel W, Novacek G. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. Eur J Clin Invest 2007;37:558-65. [DOI: 10.1111/j.1365-2362.2007.01809.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
292 Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17. [PMID: 17592647 DOI: 10.1186/1745-6215-8-17] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 5.3] [Reference Citation Analysis]
293 Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci. 2008;53:175-180. [PMID: 17551835 DOI: 10.1007/s10620-007-9840-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
294 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 487] [Article Influence: 74.7] [Reference Citation Analysis]
295 Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102. [PMID: 17234558 DOI: 10.1016/j.cgh.2006.10.025] [Cited by in Crossref: 200] [Cited by in F6Publishing: 176] [Article Influence: 13.3] [Reference Citation Analysis]
296 Biancone L, Gionchetti P, Blanco GDV, Orlando A, Annese V, Papi C, Sostegni R, D’incà R, Petruzziello C, Casa A, Sica G, Calabrese E, Campieri M, Pallone F. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. Digestive and Liver Disease 2007;39:329-37. [DOI: 10.1016/j.dld.2007.01.012] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
297 Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Alimentary Pharmacology & Therapeutics 1995;9:293-300. [DOI: 10.1111/j.1365-2036.1995.tb00384.x] [Cited by in Crossref: 137] [Cited by in F6Publishing: 112] [Article Influence: 9.1] [Reference Citation Analysis]
298 Arvind AS, Farthing MJG. Review: new aminosalicylic acid derivatives for the treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 1988;2:281-9. [DOI: 10.1111/j.1365-2036.1988.tb00699.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
299 Yoshizawa S, Kobayashi K, Katsumata T, Saigenji K, Okayasu I. Clinical usefulness of EUS for active ulcerative colitis. Gastrointest Endosc. 2007;65:253-260. [PMID: 17258984 DOI: 10.1016/j.gie.2005.10.037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
300 Yoshida N, Isozaki Y, Takagi T, Takenaka S, Uchikawa R, Arizono N, Yoshikawa T, Okanoue T. Review article: anti-tryptase therapy in inflammatory bowel disease: REVIEW: ANTI-TRYPTASE THERAPY IN IBD. Alimentary Pharmacology & Therapeutics 2006;24:249-55. [DOI: 10.1111/j.1365-2036.2006.00053.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
301 Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis. Gastroenterology 2007;132:66-75. [DOI: 10.1053/j.gastro.2006.10.011] [Cited by in Crossref: 237] [Cited by in F6Publishing: 207] [Article Influence: 15.8] [Reference Citation Analysis]
302 Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-526. [PMID: 17258720 DOI: 10.1053/j.gastro.2006.12.037] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 6.4] [Reference Citation Analysis]
303 D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 562] [Article Influence: 39.3] [Reference Citation Analysis]
304 Higgins PDR, Leung J, Schwartz M, Mapili J, Wren PA, Zimmermann EM. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis: QUANTITATIVE VALIDITY OF THE SCCAI AND SEO INDEX IN UC. Alimentary Pharmacology & Therapeutics 2007;25:333-42. [DOI: 10.1111/j.1365-2036.2006.03205.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
305 Sans M, Danese S, de la Motte C, de Souza HS, Rivera-Reyes BM, West GA, Phillips M, Katz JA, Fiocchi C. Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology. 2007;132:139-153. [PMID: 17241867 DOI: 10.1053/j.gastro.2006.10.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
306 Iizuka M, Itou H, Konno S, Shirasaka T, Horie Y, Shindo K, Watanabe S. Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis. Gut 2006;55:1523. [PMID: 16966708 DOI: 10.1136/gut.2006.099440] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
307 Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis. 2006;12:719-726. [PMID: 16917227 DOI: 10.1097/00054725-200608000-00008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
308 Kayo S, Ikura Y, Suekane T, Shirai N, Sugama Y, Ohsawa M, Adachi K, Watanabe K, Nakamura S, Fujiwara Y, Oshitani N, Higuchi K, Maeda K, Hirakawa K, Arakawa T, Ueda M. Close association between activated platelets and neutrophils in the active phase of ulcerative colitis in humans. Inflamm Bowel Dis. 2006;12:727-735. [PMID: 16917228 DOI: 10.1097/00054725-200608000-00009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
309 Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62. [PMID: 16484504 DOI: 10.1136/gut.2005.081794] [Cited by in Crossref: 307] [Cited by in F6Publishing: 256] [Article Influence: 19.2] [Reference Citation Analysis]
310 Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:841-855. [PMID: 16573787 DOI: 10.1111/j.1365-2036.2006.02846.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
311 Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, Kido M, Inoue S, Mikami S, Asada M. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology. 2006;131:1110-1121. [PMID: 17030181 DOI: 10.1053/j.gastro.2006.08.023] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 5.1] [Reference Citation Analysis]
312 Yoshida N, Isozaki Y, Takagi T, Takenaka S, Uchikawa R, Arizono N, Yoshikawa T, Okanoue T. Review article: anti-tryptase therapy in inflammatory bowel disease. Aliment Pharmacol Ther Symp Series 2006;2:249-55. [DOI: 10.1111/j.1746-6342.2006.00053.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
313 Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellström PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders. World J Gastroenterol 2006; 12(21): 3386-3392 [PMID: 16733856 DOI: 10.3748/wjg.v12.i21.3386] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
314 Van Deventer SJH, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB. A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23:1415-25. [DOI: 10.1111/j.1365-2036.2006.02910.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
315 Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos GJ. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085-1091. [PMID: 16306771 DOI: 10.1097/01.mib.0000187980.08686.18] [Cited by in Crossref: 95] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
316 Tursi A, Brandimarte G, Elisei W, Inchingolo CD, Aiello F. Epithelial Cell Proliferation of the Colonic Mucosa in Different Degrees of Colonic Diverticular Disease. Journal of Clinical Gastroenterology 2006;40:306-11. [DOI: 10.1097/01.mcg.0000210093.54425.72] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
317 Ingram JR, Rhodes J, Evans BK, Newcombe RG, Thomas GA. Comparative study of enema retention and preference in ulcerative colitis. Postgrad Med J 2005;81:594-8. [PMID: 16143691 DOI: 10.1136/pgmj.2004.031690] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
318 Roblin X, Germain E, Phelip J, Ducros V, Pofelski J, Heluwaert F, Oltean P, Faucheron J, Bonaz B. Hyperhomocystéinémie et facteurs associés au cours des MICI : étude prospective chez 81 patients. La Revue de Médecine Interne 2006;27:106-10. [DOI: 10.1016/j.revmed.2005.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
319 Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006; 12(4): 520-525 [PMID: 16489663 DOI: 10.3748/wjg.v12.i4.520] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
320 Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005;11 Suppl 1:S22-S28. [PMID: 16254479 DOI: 10.1097/01.mib.0000184849.38816.39] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
321 Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL, Srivastava ED, Evans BK, Williams GT, Newcombe RG, Courtney E, Pillai S. A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol. 2005;3:1107-1114. [PMID: 16271342 DOI: 10.1016/s1542-3565(05)00849-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
322 Gross V, Bar-meir S, Lavy A, Mickisch O, Tulassay Z, Pronai L, Kupcinskas L, Kiudelis G, Pokrotnieks J, Kovacs A, Faszczyk M, Razbadauskas A, Margus B, Stolte M, Muller R, Greinwald R; THE INTERNATIONAL BUDESONIDE FOAM STUDY GROUPsss. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006;23:303-12. [DOI: 10.1111/j.1365-2036.2006.02743.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
323 Makiyama K, Takeshima F, Hamamoto T. Efficacy of Rebamipide Enemas in Active Distal Ulcerative Colitis and Proctitis: A Prospective Study Report. Dig Dis Sci 2005;50:2323-9. [DOI: 10.1007/s10620-005-3055-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
324 Brunner M, Vogelsang H, Greinwald R, Kletter K, Kvaternik H, Schrolnberger C, Eichler HG, Brunner H, Dudczak R, Müller M. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2005;22:463-470. [PMID: 16128685 DOI: 10.1111/j.1365-2036.2005.02571.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
325 Akbayir N, Çaliş AB, Alkim C, Sökmen HM, Erdem L, Özbal A, Bölükbaş F, Akbayir N. Sensorineural Hearing Loss in Patients with Inflammatory Bowel Disease: A Subclinical Extraintestinal Manifestation. Dig Dis Sci 2005;50:1938-45. [DOI: 10.1007/s10620-005-2964-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
326 Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. The impact of the fecal stream and stasis on immunologic reactions in ileal pouch after restorative proctocolectomy for ulcerative colitis: a prospective, pilot study. Am J Gastroenterol 2005;100:2248-53. [PMID: 16181377 DOI: 10.1111/j.1572-0241.2005.50617.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
327 Maclean CH, Mojica WA, Newberry SJ, Pencharz J, Garland RH, Tu W, Hilton LG, Gralnek IM, Rhodes S, Khanna P, Morton SC. Systematic review of the effects of n−3 fatty acids in inflammatory bowel disease. The American Journal of Clinical Nutrition 2005;82:611-9. [DOI: 10.1093/ajcn/82.3.611] [Cited by in Crossref: 73] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
328 Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis. 2005;11:589-596. [PMID: 15905707 DOI: 10.1097/01.mib.0000161917.97136.e2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
329 Furlan R, Ardizzone S, Palazzolo L, Rimoldi A, Perego F, Barbic F, Bevilacqua M, Vago L, Bianchi Porro G, Malliani A. Sympathetic overactivity in active ulcerative colitis: effects of clonidine. Am J Physiol Regul Integr Comp Physiol. 2006;290:R224-R232. [PMID: 16123227 DOI: 10.1152/ajpregu.00442.2005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 3.8] [Reference Citation Analysis]
330 Mahmood A, Melley L, Fitzgerald AJ, Ghosh S, Playford RJ. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2005;21:1357-1364. [PMID: 15932366 DOI: 10.1111/j.1365-2036.2005.02436.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
331 Gionchetti P, D’Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39:291-297. [PMID: 15758622 DOI: 10.1097/01.mcg.0000155124.74548.61] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
332 Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46. [PMID: 15984978 DOI: 10.1111/j.1572-0241.2005.41794.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 430] [Article Influence: 28.6] [Reference Citation Analysis]
333 Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960-5. [PMID: 15951542 DOI: 10.1136/gut.2004.060103] [Cited by in Crossref: 242] [Cited by in F6Publishing: 190] [Article Influence: 14.2] [Reference Citation Analysis]
334 Seidner DL, Lashner BA, Brzezinski A, Banks PL, Goldblum J, Fiocchi C, Katz J, Lichtenstein GR, Anton PA, Kam LY. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3:358-369. [PMID: 15822041 DOI: 10.1016/s1542-3565(04)00672-x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
335 Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005;54:782-8. [PMID: 15888785 DOI: 10.1136/gut.2004.056358] [Cited by in Crossref: 169] [Cited by in F6Publishing: 158] [Article Influence: 9.9] [Reference Citation Analysis]
336 Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study. Am J Gastroenterol 2005;100:1370-5. [PMID: 15929772 DOI: 10.1111/j.1572-0241.2005.41412.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 3.3] [Reference Citation Analysis]
337 Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M, Gasbarrini G, Cittadini A, Gasbarrini A. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol 2005;100:886-95. [PMID: 15784037 DOI: 10.1111/j.1572-0241.2005.41469.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 4.8] [Reference Citation Analysis]
338 Summers RW, Elliott DE, Urban JF, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology 2005;128:825-32. [DOI: 10.1053/j.gastro.2005.01.005] [Cited by in Crossref: 527] [Cited by in F6Publishing: 463] [Article Influence: 31.0] [Reference Citation Analysis]
339 Roblin X, Serre-debeauvais F, Phelip J, Faucheron J, Hardy G, Chartier A, Helluwaert F, Bessard G, Bonaz B. 6-Tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005;21:829-39. [DOI: 10.1111/j.1365-2036.2005.02419.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
340 Pica R, Paoluzi OA, Iacopini F, Marcheggiano A, Crispino P, Rivera M, Bella A, Consolazio A, Paoluzi P. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis. 2004;10:731-736. [PMID: 15626890 DOI: 10.1097/00054725-200411000-00006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
341 Reimund JM, Bonaz B, Gompel M, Michot F, Moreau J, Veyrac M, Wagner Ballon J. [Induction and maintenance of remission in ulcerative colitis]. Gastroenterol Clin Biol 2004;28:992-1004. [PMID: 15672571 DOI: 10.1016/s0399-8320(04)95177-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
342 Seksik P, Contou JF, Ducrotté P, Faucheron JL, de Parades V. [The treatment of distal ulcerative colitis]. Gastroenterol Clin Biol 2004;28:964-73. [PMID: 15672568 DOI: 10.1016/s0399-8320(04)95174-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
343 Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev 2005;57:281-302. [PMID: 15555743 DOI: 10.1016/j.addr.2004.08.008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
344 Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto M, Nishimura N, Yasue K, Matsumoto K. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004;20:783-792. [PMID: 15379839 DOI: 10.1111/j.1365-2036.2004.02189.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
345 Yigitler C, Gulec B, Aydogan H, Ozcan A, Kilinc M, Yigit T, Kozak O, Pekcan M. Effect of mesalazine, metronidazole and gentamicin on bacterial translocation in experimental colitis. J Gastroenterol Hepatol 2004;19:1179-86. [DOI: 10.1111/j.1440-1746.2004.03457.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
346 Maunder RG, Greenberg GR. Comparison of a Disease Activity Index and Patients’ Self-Reported Symptom Severity in Ulcerative Colitis: . Inflammatory Bowel Diseases 2004;10:632-6. [DOI: 10.1097/00054725-200409000-00020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
347 Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85. [PMID: 15233681 DOI: 10.1111/j.1572-0241.2004.40036.x] [Cited by in Crossref: 440] [Cited by in F6Publishing: 382] [Article Influence: 24.4] [Reference Citation Analysis]
348 Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004;99:1122-8. [PMID: 15180735 DOI: 10.1111/j.1572-0241.2004.11481.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 4.8] [Reference Citation Analysis]
349 Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterology Clinics of North America 2004;33:235-50. [DOI: 10.1016/j.gtc.2004.02.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
350 Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-41. [PMID: 12970136 DOI: 10.1136/gut.52.10.1435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
351 Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-41. [PMID: 12970136 DOI: 10.1136/gut.52.10.1435] [Cited by in Crossref: 171] [Cited by in F6Publishing: 181] [Article Influence: 9.0] [Reference Citation Analysis]
352 Campieri M, Adamo S, Valpiani D, D'Arienzo A, D'Albasio G, Pitzalis M, Cesari P, Casetti T, Castiglione GN, Rizzello F, Manguso F, Varoli G, Gionchetti P. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 2003;17:1471-1480. [PMID: 12823149 DOI: 10.1046/j.1365-2036.2003.01609.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 4.2] [Reference Citation Analysis]
353 Vernia P, Annese V, Bresci G, d'Albasio G, D'Incà R, Giaccari S, Ingrosso M, Mansi C, Riegler G, Valpiani D. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest. 2003;33:244-248. [PMID: 12641543 DOI: 10.1046/j.1365-2362.2003.01130.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 123] [Article Influence: 6.5] [Reference Citation Analysis]
354 Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, Cottone M, Miglioli M, Prantera C, Sturniolo G. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis. 2002;34:787-793. [PMID: 12546514 DOI: 10.1016/s1590-8658(02)80072-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
355 Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003;124:1249-64. [PMID: 12730866 DOI: 10.1016/s0016-5085(03)00289-0] [Cited by in Crossref: 139] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
356 Wallace J. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease. Digestive and Liver Disease 2003;35:S35-40. [DOI: 10.1016/s1590-8658(03)00050-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
357 Rizzello F, Gionchetti P, D’Arienzo A, Manguso F, Di Matteo G, Annese V, Valpiani D, Casetti T, Adamo S, Prada A. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2002;16:1109-1116. [PMID: 12030952 DOI: 10.1046/j.1365-2036.2002.01298.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 5.0] [Reference Citation Analysis]
358 Li FX, Sutherland LR. Assessing disease activity and disease activity indices for inflammatory bowel disease. Curr Gastroenterol Rep 2002;4:490-6. [DOI: 10.1007/s11894-002-0025-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
359 Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-84. [PMID: 12385442 DOI: 10.1111/j.1572-0241.2002.06026.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 110] [Article Influence: 6.4] [Reference Citation Analysis]
360 Ardizzone S, Bianchi Porro G. Comparative tolerability of therapies for ulcerative colitis. Drug Saf. 2002;25:561-582. [PMID: 12113642 DOI: 10.2165/00002018-200225080-00003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
361 Goto M, Okamoto Y, Yamamoto M, Aki H. Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs. J Pharm Pharmacol. 2001;53:1711-1720. [PMID: 11804402 DOI: 10.1211/0022357011778115] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
362 Malchow H, Gertz B. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther. 2002;16:415-423. [PMID: 11876694 DOI: 10.1046/j.1365-2036.2002.01199.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
363 Katz S. Update in medical therapy of ulcerative colitis: a practical approach. J Clin Gastroenterol. 2002;34:397-407. [PMID: 11907350 DOI: 10.1097/00004836-200204000-00004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
364 Gisbert JP, Gomollón F, Maté J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci. 2002;47:471-488. [PMID: 11911332 DOI: 10.1023/A:1017987229718] [Cited by in Crossref: 74] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
365 Tremaine WJ, Brzezinski A, Katz JA, Wolf DC, Fleming TJ, Mordenti J, Strenkoski-nix LC, Kurth MC; THE AXYS ULCERATIVE COLITIS STUDY GROUP. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study: TRYPTASE INHIBITOR FOR ULCERATIVE COLITIS. Alimentary Pharmacology & Therapeutics 2002;16:407-13. [DOI: 10.1046/j.1365-2036.2002.01194.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 3.2] [Reference Citation Analysis]
366 Lombardi DA, Feller ER, Shah SA. Medical management of inflammatory bowel disease in the new millennium. Compr Ther 2002;28:39-49. [DOI: 10.1007/s12019-002-0041-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
367 Farup PG, Hinterleitner TA, Lukás M, Hébuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7:237-242. [PMID: 11515850 DOI: 10.1097/00054725-200108000-00009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
368 Naganuma M, Iwao Y, Ogata H, Inoue N, Funakoshi S, Yamamoto S, Nakamura Y, Ishii H, Hibi T. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001;7:221-225. [PMID: 11515848 DOI: 10.1097/00054725-200108000-00007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
369 Falasco G, Zinicola R, Forbes A. Immunosuppressants in distal ulcerative colitis: IMMUNOSUPPRESSION IN DISTAL ULCERATIVE COLITIS. Alimentary Pharmacology & Therapeutics 2002;16:181-7. [DOI: 10.1046/j.1365-2036.2002.01170.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
370 Oshima T, Pavlick K, Grisham MB, Jordan P, Manas K, Joh T, Itoh M, Alexander JS. Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy. Aliment Pharmacol Ther 2001;15:1211-8. [PMID: 11472325 DOI: 10.1046/j.1365-2036.2001.01048.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
371 Buchman AL, Fife C, Torres C, Smith L, Aristizibal J. Hyperbaric oxygen therapy for severe ulcerative colitis. J Clin Gastroenterol 2001;33:337-9. [PMID: 11588553 DOI: 10.1097/00004836-200110000-00018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
372 Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001;96:3323-8. [PMID: 11774944 DOI: 10.1111/j.1572-0241.2001.05333.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 66] [Article Influence: 0.7] [Reference Citation Analysis]
373 Rizzello F, Gionchetti P, Galeazzi R, Novelli G, Valpiani D, D'Arienzo A, Manguso F, Castiglione G, Varoli G, Campieri M. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther 2001;18:261-71. [PMID: 11841196 DOI: 10.1007/BF02850196] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
374 Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L, Ganio E, Usai P, Campieri M, Fornaciari G. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001;15:251-256. [PMID: 11148445 DOI: 10.1046/j.1365-2036.2001.00913.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
375 De Vos M. Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet 2000;39:85-97. [PMID: 10976656 DOI: 10.2165/00003088-200039020-00001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
376 Sambuelli A, Diez RA, Sugai E, Boerr L, Negreira S, Gil A, Camartino G, Huernos S, Doldán I, Felstiner D, Bai JC. Serum transforming growth factor-beta1 levels increase in response to successful anti-inflammatory therapy in ulcerative colitis. Aliment Pharmacol Ther 2000;14:1443-9. [PMID: 11069315 DOI: 10.1046/j.1365-2036.2000.00861.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
377 Mahadevan U, Tremaine WJ, Johnson T, Pike GM, Mays DC, Lipsky JJ, Sandborn WJ. Intravenous Azathioprine in Severe Ulcerative Colitis: A Pilot Study. American Journal of Gastroenterology 2000;95:3463-8. [DOI: 10.1111/j.1572-0241.2000.03362.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
378 Chang L, Munakata J, Mayer EA, Schmulson MJ, Johnson TD, Bernstein CN, Saba L, Naliboff B, Anton PA, Matin K. Perceptual responses in patients with inflammatory and functional bowel disease. Gut 2000;47:497-505. [PMID: 10986209 DOI: 10.1136/gut.47.4.497] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 6.5] [Reference Citation Analysis]
379 Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000;95:1628-1636. [PMID: 10925961 DOI: 10.1111/j.1572-0241.2000.02180.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 82] [Article Influence: 4.4] [Reference Citation Analysis]
380 Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263-1276. [PMID: 10811338 DOI: 10.1111/j.1572-0241.2000.01940.x] [Cited by in Crossref: 190] [Cited by in F6Publishing: 154] [Article Influence: 8.6] [Reference Citation Analysis]
381 Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, Marcheggiano A, Pallone F, Caprilli R, Torsoli A. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci. 2000;45:976-981. [PMID: 10795763 DOI: 10.1023/a:1005537411244] [Cited by in Crossref: 79] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
382 Greca FH, Biondo-simões MDLP, Ioshi S, Santos EAAD, Chin EWK, El Tawil II, Stalhschmidt FL. Cicatrização de anastomoses do cólon esquerdo com doença inflamatória: estudo experimental em ratos. Acta Cir Bras 2000;15:41-6. [DOI: 10.1590/s0102-86502000000700009] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
383 Frieri G, Pimpo MT, Palumbo GC, Onori L, Viscido A, Latella G, Galletti B, Pantaleoni GC, Caprilli R. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther. 1999;13:1413-1417. [PMID: 10571596 DOI: 10.1046/j.1365-2036.1999.00642.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
384 Ludwig D, Wiener S, Brüning A, Schwarting K, Jantschek G, Fellermann K, Stahl M, Stange EF. Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study. Gut 1999;45:546-52. [PMID: 10486363 DOI: 10.1136/gut.45.4.546] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
385 Kaya E, Gür ES, Ozgüç H, Bayer A, Tokyay R. L-glutamine enemas attenuate mucosal injury in experimental colitis. Dis Colon Rectum. 1999;42:1209-1215. [PMID: 10496564 DOI: 10.1007/bf02238577] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
386 Wallace JL, Vergnolle N, Muscará MN, Asfaha S, Chapman K, McKnight W, Del Soldato P, Morelli A, Fiorucci S. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 1999;117:557-66. [PMID: 10464131 DOI: 10.1016/s0016-5085(99)70448-8] [Cited by in Crossref: 66] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
387 Soweid AM, Chak A, Katz JA, Sivak MV. Catheter probe–assisted endoluminal US in inflammatory bowel disease. Gastrointestinal Endoscopy 1999;50:41-6. [DOI: 10.1016/s0016-5107(99)70342-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
388 Michetti P, Peppercorn MA. MEDICAL THERAPY OF SPECIFIC CLINICAL PRESENTATIONS. Gastroenterology Clinics of North America 1999;28:353-70. [DOI: 10.1016/s0889-8553(05)70060-1] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
389 Gionchetti P, Ardizzone S, Benvenuti ME, Bianchi Porro G, Biasco G, Cesari P, D'albasio G, De Franchis R, Monteleone G, Pallone F. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther. 1999;13:381-388. [PMID: 10102972 DOI: 10.1046/j.1365-2036.1999.00482.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 2.1] [Reference Citation Analysis]
390 Prantera C, Cottone M, Pallone F, Annese V, Franzè A, Cerutti R, Bianchi Porro G. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116:521-6. [PMID: 10029609 DOI: 10.1016/s0016-5085(99)70172-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
391 Lee JC, Cevallos AM, Naeem A, Lennard-Jones JE, Farthing MJ. Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells. Gut 1999;44:196-202. [PMID: 9895378 DOI: 10.1136/gut.44.2.196] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
392 Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology. 1998;115:525-532. [PMID: 9721148 DOI: 10.1016/s0016-5085(98)70131-3] [Cited by in Crossref: 128] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
393 d'Albasio G, Paoluzi P, Campieri M, Bianchi Porro G, Pera A, Prantera C, Sturniolo GC, Miglioli M. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol. 1998;93:799-803. [PMID: 9625131 DOI: 10.1111/j.1572-0241.1998.228_a.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
394 Ardizzone S, Bianchi Porro G. A practical guide to the management of distal ulcerative colitis. Drugs. 1998;55:519-542. [PMID: 9561342 DOI: 10.2165/00003495-199855040-00004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis]
395 Xia B, Guo HJ, Crusius J, Deng CS, Meuwissen S, Pena A. In vitro production of TNFα, IL-6 and sIL-2R in Chinese patients with ulcerative colitis. World J Gastroenterol 1998; 4(3): 252-255 [PMID: 11819289 DOI: 10.3748/wjg.v4.i3.252] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
396 Hanauer SB. Dose-Ranging Study of Mesalamine (PENTASA) Enemas in the Treatment of Acute Ulcerative Proctosigmoiditis: Results of a Multicentered Placebo-Controlled Trial: . Inflammatory Bowel Diseases 1998;4:79-83. [DOI: 10.1097/00054725-199805000-00001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
397 Bickston SJ, Cominelli F. Inflammatory bowel disease: Short- and long- term treatments. Disease-a-Month 1998;44:141-72. [DOI: 10.1016/s0011-5029(98)90008-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
398 Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Miglioli M, Campieri M. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41:93-97. [PMID: 9510317 DOI: 10.1007/BF02236902] [Cited by in Crossref: 98] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
399 Otten MH, De Haas G, Van den Ende R. Colonic spread of 5-ASA enemas in healthy individuals, with a comparison of their physical and chemical characteristics. Aliment Pharmacol Ther. 1997;11:693-697. [PMID: 9305477 DOI: 10.1046/j.1365-2036.1997.00199.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
400 Gionchetti P, Venturi A, Rizzello F, Corbelli C, Fanti S, Ferretti M, Boschi S, Miglioli M, Campieri M. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther. 1997;11:679-684. [PMID: 9305475 DOI: 10.1046/j.1365-2036.1997.00183.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
401 Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther. 1997;11:663-671. [PMID: 9305473 DOI: 10.1046/j.1365-2036.1997.00208.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 1.9] [Reference Citation Analysis]
402 Bondesen S. INTESTINAL FATE OF 5-AMINOSALICYLIC ACID: REGIONAL AND SYSTEMIC KINETIC STUDIES IN RELATION TO INFLAMMATORY BOWEL DISEASE. Pharmacology & Toxicology 1997;81:1-30. [DOI: 10.1111/j.1600-0773.1997.tb01944.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
403 Teshima T, Hanks GE, Hanlon AL, Peter RS, Schultheiss TE. Rectal bleeding after conformal 3D treatment of prostate cancer: Time to occurrence, response to treatment and duration of morbidity. International Journal of Radiation Oncology*Biology*Physics 1997;39:77-83. [DOI: 10.1016/s0360-3016(97)00301-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
404 Brown J, Haines S, Wilding IR. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol Ther 1997;11:685-91. [DOI: 10.1046/j.1365-2036.1997.00193.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
405 Borum ML, Ginsberg A. Hypersensitivity to 5-ASA suppositories. Dig Dis Sci 1997;42:1076-8. [PMID: 9149065 DOI: 10.1023/a:1018857607739] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
406 Borum ML, Ginsberg A. Hypersensitivity to 5-ASA suppositories. Dig Dis Sci. 1997;42:1076-1078. [PMID: 9149065 DOI: 10.1023/a: 1018857607739] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
407 Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, Harig JM, Keshavarzian A, Robinson M, Sellin JH, Weinberg D, Vidican DE, Flemal KL, Rademaker AW. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997;40:485-91. [PMID: 9176076 DOI: 10.1136/gut.40.4.485] [Cited by in Crossref: 182] [Cited by in F6Publishing: 161] [Article Influence: 7.3] [Reference Citation Analysis]
408 Richter F, Scheppach W. 7 Innovations in topical therapy. Baillière's Clinical Gastroenterology 1997;11:97-109. [DOI: 10.1016/s0950-3528(97)90056-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
409 Sutherland LR, Hanauer S, Scholmerich J. Standards for Trials of Therapy in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 1997;3:277-83. [DOI: 10.1097/00054725-199712000-00005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
410 Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci. 1996;41:2254-2259. [PMID: 8943981 DOI: 10.1007/bf02071409] [Cited by in Crossref: 133] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
411 Irvine E, Feagan B, Wong C. Does self-administration of a quality of life index for inflammatory bowel disease change the results? Journal of Clinical Epidemiology 1996;49:1177-85. [DOI: 10.1016/0895-4356(96)00136-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.0] [Reference Citation Analysis]
412 Kolkman JJ, Falke TH, Roos JC, Van Dijk DH, Bannink IM, Den Hollander W, Cuesta MA, Peña AS, Meuwissen SG. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings. Dig Dis Sci 1996;41:641-50. [PMID: 8674383 DOI: 10.1007/BF02213118] [Cited by in Crossref: 45] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
413 Schoonjans R, De Vos M, Schelfhout AM, Praet M, Elewaut A. Distribution and concentrations of 5-aminosalicylic acid in rectosigmoid biopsy specimens after rectal administration. Dis Colon Rectum 1996;39:788-93. [PMID: 8674372 DOI: 10.1007/BF02054445] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
414 Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996;71:431-6. [PMID: 8628021 DOI: 10.4065/71.5.431] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 3.7] [Reference Citation Analysis]
415 Elson CO. The basis of current and future therapy for inflammatory bowel disease. The American Journal of Medicine 1996;100:656-62. [DOI: 10.1016/s0002-9343(96)00049-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
416 Kirschner BS. Ulcerative colitis in children. Pediatr Clin North Am 1996;43:235-54. [PMID: 8596682 DOI: 10.1016/s0031-3955(05)70404-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
417 Lémann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, Elewaut A, Belaiche J, Froguel E, Modigliani R. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9:557-562. [PMID: 8580278 DOI: 10.1111/j.1365-2036.1995.tb00421.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 3.5] [Reference Citation Analysis]
418 Bouma G, Oudkerk Pool M, Scharenberg JG, Kolkman JJ, von Blomberg BM, Scheper RJ, Meuwissen SG, Peña AS. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995;30:1095-100. [PMID: 8578170 DOI: 10.3109/00365529509101613] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.7] [Reference Citation Analysis]
419 Lee FI, Jewell DP, Mani V, Keighley MR, Kingston RD, Record CO, Grace RH, Daniels S, Patterson J, Smith K. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996;38:229-33. [PMID: 8801202 DOI: 10.1136/gut.38.2.229] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 2.0] [Reference Citation Analysis]
420 Oudkerk Pool M, Bouma G, Visser JJ, Kolkman JJ, Tran DD, Meuwissen SG, Peña AS. Serum nitrate levels in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1995;30:784-8. [PMID: 7481547 DOI: 10.3109/00365529509096328] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 1.8] [Reference Citation Analysis]
421 Bitton A, Peppercorn MA. MEDICAL MANAGEMENT OF SPECIFIC CLINICAL PRESENTATIONS. Gastroenterology Clinics of North America 1995;24:541-58. [DOI: 10.1016/s0889-8553(21)00210-7] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
422 Griffin MG, Miner PB. CONVENTIONAL DRUG THERAPY IN INFLAMMATORY BOWEL DISEASE. Gastroenterology Clinics of North America 1995;24:509-21. [DOI: 10.1016/s0889-8553(21)00208-9] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
423 Oudkerk Pool M, Bouma G, Meuwissen SG, von Blomberg BM, van de Merwe JP, Devillé WL, Fonk JC, Peña AS. Serological markers to differentiate between ulcerative colitis and Crohn's disease. J Clin Pathol 1995;48:346-50. [PMID: 7615855 DOI: 10.1136/jcp.48.4.346] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
424 Wilding IR, Kenyon CJ, Chauhan S, Hooper G, Marshall S, McCracken JS, Staab HJ, Armbrecht J. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 1995;9:161-6. [PMID: 7605856 DOI: 10.1111/j.1365-2036.1995.tb00365.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
425 Farup PG, Hovde O, Halvorsen FA, Raknerud N, Brodin U. Mesalazine suppositories vs hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol. 1995;30:164-170. [PMID: 7732340 DOI: 10.3109/00365529509093256] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 2.1] [Reference Citation Analysis]
426 Layer PH, Goebell H, Keller J, Dignass A, Klotz U. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995;108:1427-33. [DOI: 10.1016/0016-5085(95)90691-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 2.4] [Reference Citation Analysis]
427 Bortoluzzi F, Valentini M, Cernigoi C, Toffoli G, Boiocchi M, Poletti M, Sozzi M, Fornasarig M, Cannizzaro R, Bertolissi E. DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease. Gut 1995;36:50-4. [PMID: 7890236 DOI: 10.1136/gut.36.1.50] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
428 Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995;40:296-304. [PMID: 7851193 DOI: 10.1007/bf02065413] [Cited by in Crossref: 100] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
429 Lee JC, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology. 1995;108:428-433. [PMID: 7835584 DOI: 10.1016/0016-5085(95)90070-5] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 1.9] [Reference Citation Analysis]
430 Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1995;1:117-34. [DOI: 10.1002/ibd.3780010206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
431 Bitton A, Peppercorn MA. Medical Therapy of Ulcerative Proctitis and Proctosigmoiditis, Including Refractory Disease: . Inflammatory Bowel Diseases 1995;1:207-19. [DOI: 10.1097/00054725-199509000-00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
432 Hodgson HJF, Bhatti M. Assessment of Disease Activity in Ulcerative Colitis and Crohnʼs Disease: . Inflammatory Bowel Diseases 1995;1:117-34. [DOI: 10.1097/00054725-199506000-00005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
433 Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35. [DOI: 10.1016/0016-5085(94)90394-8] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 3.5] [Reference Citation Analysis]
434 Mantzaris GJ, Hatzis A, Petraki K, Spiliadi C, Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Diseases of the Colon & Rectum 1994;37:58-62. [DOI: 10.1007/bf02047216] [Cited by in Crossref: 49] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
435 Campieri M, Paoluzi P, D'albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: A multicenter comparative trial with 5-ASA enema. Digest Dis Sci 1993;38:1843-50. [DOI: 10.1007/bf01296108] [Cited by in Crossref: 50] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
436 Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993;38:1722-1734. [PMID: 8359087 DOI: 10.1007/bf01303184] [Cited by in Crossref: 391] [Cited by in F6Publishing: 194] [Article Influence: 13.5] [Reference Citation Analysis]
437 Peppercorn MA. A critical evaluation of the therapeutic benefits and side-effects of aminosalicylate analogues in the treatment of inflammatory bowel disease. Inflammopharmacology 1993;2:263-76. [DOI: 10.1007/bf02660617] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
438 Bonner GF, Ruderman WB. 5-aminosalicylic acid preparations in the treatment of inflammatory bowel disease. Inflammopharmacology 1993;2:247-62. [DOI: 10.1007/bf02660616] [Reference Citation Analysis]
439 Pullan RD, Ganesh S, Mani V, Morris J, Evans BK, Williams GT, Rhodes J. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 1993;34:676-9. [PMID: 8504970 DOI: 10.1136/gut.34.5.676] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 1.6] [Reference Citation Analysis]
440 Tran D, Visser J, Pool M, Cuesta M, Hoekman K, Salvador Peña A, Meuwissen S. Enhanced systemic nitric oxide production in inflammatory bowel disease. The Lancet 1993;341:1150. [DOI: 10.1016/0140-6736(93)93166-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
441 Selby W. Current management of inflammatory bowel disease. J Gastroenterol Hepatol 1993;8:70-83. [DOI: 10.1111/j.1440-1746.1993.tb01178.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
442 Oudkerk Pool M, Ellerbroek PM, Ridwan BU, Goldschmeding R, von Blomberg BM, Peña AS, Dolman KM, Bril H, Dekker W, Nauta JJ. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993;34:46-50. [PMID: 8432451 DOI: 10.1136/gut.34.1.46] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 2.8] [Reference Citation Analysis]
443 Rogers AI, Coelho-Borges S. Medical therapy in Crohn's disease. Postgrad Med 1992;92:169-73, 177-8, 183 passim. [PMID: 1360652 DOI: 10.1080/00325481.1992.11701558] [Reference Citation Analysis]
444 Campieri M, Corbelli C, Gionchetti P, Brignola C, Belluzzi A, Di Febo G, Zagni P, Brunetti G, Miglioli M, Barbara L. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Digest Dis Sci 1992;37:1890-7. [DOI: 10.1007/bf01308084] [Cited by in Crossref: 69] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
445 Lin SY, Ayres JW. Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm Res 1992;9:1128-31. [PMID: 1409392 DOI: 10.1023/a:1015887318767] [Cited by in Crossref: 52] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
446 Senagore AJ, MacKeigan JM, Scheider M, Ebrom JS. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992;35:923-7. [PMID: 1395977 DOI: 10.1007/BF02253492] [Cited by in Crossref: 72] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
447 De Vos M, Verdievel H, Schoonjans R, Praet M, Bogaert M, Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992;33:1338-42. [PMID: 1446856 DOI: 10.1136/gut.33.10.1338] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 2.4] [Reference Citation Analysis]
448 Kamm MA, Senapati A. Drug management of ulcerative colitis. BMJ 1992;305:35-8. [PMID: 1638200 DOI: 10.1136/bmj.305.6844.35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
449 Geier DL, Miner PB. New therapeutic agents in the treatment of inflammatory bowel disease. The American Journal of Medicine 1992;93:199-208. [DOI: 10.1016/0002-9343(92)90051-c] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
450 Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, Richter F, Dusel G, Kasper H. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992;103:51-56. [PMID: 1612357 DOI: 10.1016/0016-5085(92)91094-K] [Cited by in Crossref: 504] [Cited by in F6Publishing: 157] [Article Influence: 16.8] [Reference Citation Analysis]
451 Linn FV, Peppercorn MA. Drug therapy for inflammatory bowel disease: Part I. The American Journal of Surgery 1992;164:85-9. [DOI: 10.1016/s0002-9610(05)80654-3] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
452 Polson RJ, Misiewicz JJ. Medical management of severe inflammatory disease of the rectum and distal colon: non-nutritional aspects. Baillieres Clin Gastroenterol 1992;6:1-26. [PMID: 1586763 DOI: 10.1016/0950-3528(92)90015-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.0] [Reference Citation Analysis]
453 Thomson AB. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1991;5:449-70. [PMID: 1793778 DOI: 10.1111/j.1365-2036.1991.tb00515.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
454 Sharma MP, Duphare HV, Dasarathy S. A prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis. J Gastroenterol Hepatol 1992;7:173-7. [DOI: 10.1111/j.1440-1746.1992.tb00957.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
455 van Hoogdalem EJ, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokinet 1991;21:110-28. [PMID: 1884566 DOI: 10.2165/00003088-199121020-00003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
456 De Vos M, Verdievel H, Schoonjans R, Beke R, De Weerdt GA, Barbier F. High-performance liquid chromatographic assay for the determination of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid concentrations in endoscopic intestinal biopsy in humans. J Chromatogr 1991;564:296-302. [PMID: 1860925 DOI: 10.1016/0378-4347(91)80094-s] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
457 Almer S, Norlander B, Ström M, Osterwald H. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. Scand J Gastroenterol 1991;26:327-35. [PMID: 1853156 DOI: 10.3109/00365529109025050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
458 Breuer RI, Buto SK, Christ ML, Bean J, Vernia P, Paoluzi P, Di Paolo MC, Caprilli R. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci. 1991;36:185-187. [PMID: 1988261 DOI: 10.1007/bf01300754] [Cited by in Crossref: 193] [Cited by in F6Publishing: 48] [Article Influence: 6.2] [Reference Citation Analysis]
459 Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Brunetti G, Miglioli M, Barbara L. Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis 1990;5:79-81. [PMID: 2193075 DOI: 10.1007/BF00298473] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
460 Biddle WL, Miner PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990;99:113-8. [DOI: 10.1016/0016-5085(90)91237-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
461 d'Albasio G, Trallori G, Ghetti A, Milla M, Nucci A, Pacini F, Morettini A. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Diseases of the Colon & Rectum 1990;33:394-7. [DOI: 10.1007/bf02156265] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
462 Farmer RG. Evolution of the concept of proctosigmoiditis: clinical observation. Med Clin North Am 1990;74:91-102. [PMID: 2404183 DOI: 10.1016/s0025-7125(16)30588-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
463 Sellinger M, Barrett C, Malle P, Gordon ER, Boyer JL. Cryptic Na+,K(+)-ATPase activity in rat liver canalicular plasma membranes: evidence for its basolateral origin. Hepatology 1990;11:223-9. [PMID: 2155168 DOI: 10.1002/hep.1840110211] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
464 Tucker MA, Smith TJ. Acetylation of 5-aminosalicylate by hamster colon arylamineN-acetyltransferase. J Appl Toxicol 1990;10:73-4. [DOI: 10.1002/jat.2550100114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
465 Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989;38:500-523. [PMID: 2684592 DOI: 10.2165/00003495-198938040-00003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 1.7] [Reference Citation Analysis]
466 Ruderman WB. Newer Pharmacologic Agents for the Therapy of Inflammatory Bowel Disease. Medical Clinics of North America 1990;74:133-53. [DOI: 10.1016/s0025-7125(16)30591-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
467 Sutherland LR. Topical Treatment of Ulcerative Colitis. Medical Clinics of North America 1990;74:119-31. [DOI: 10.1016/s0025-7125(16)30590-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
468 Vitti RA, Meyers F, Knight LC, Siegel JA, Malmud LS, Fisher RS. Quantitative distribution of radiolabeled 5-Aminosalicylic acid enemas in patients with left-sided ulcerative colitis. Digest Dis Sci 1989;34:1792-7. [DOI: 10.1007/bf01540060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
469 Camilleri M, Proano M. Advances in the assessment of disease activity in inflammatory bowel disease. Mayo Clin Proc 1989;64:800-7. [PMID: 2671519 DOI: 10.1016/s0025-6196(12)61753-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
470 Baum CA, Biddle WL, Miner PB. Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis. Dig Dis Sci. 1989;34:758-760. [PMID: 2714149 DOI: 10.1007/bf01540349] [Cited by in Crossref: 83] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
471 Järnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 1989;37:73-86. [PMID: 2651087 DOI: 10.2165/00003495-198937010-00005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.0] [Reference Citation Analysis]
472 Ginsberg AL. Topical Salicylate Therapy (4-ASA and 5-ASA Enemas). Gastroenterology Clinics of North America 1989;18:35-42. [DOI: 10.1016/s0889-8553(21)00423-4] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
473 Peppercorn MA. Update on the Aminosalicylates: A Promise Fulfilled. Gastroenterology 1988;95:1677-80. [DOI: 10.1016/s0016-5085(88)80096-9] [Cited by in Crossref: 5] [Article Influence: 0.1] [Reference Citation Analysis]
474 . Recognition and management of inflammatory bowel disease in children and adolescents. Current Problems in Pediatrics 1988;18:383-437. [DOI: 10.1016/0045-9380(88)90032-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
475 Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383-1389. [PMID: 2896139 DOI: 10.1016/0016-5085(88)90677-4] [Cited by in Crossref: 131] [Cited by in F6Publishing: 126] [Article Influence: 3.9] [Reference Citation Analysis]
476 Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988;29:669-74. [PMID: 2899536 DOI: 10.1136/gut.29.5.669] [Cited by in Crossref: 139] [Cited by in F6Publishing: 138] [Article Influence: 4.1] [Reference Citation Analysis]
477 Biddle WL, Greenberger NJ, Swan J, Mcphee MS, Miner PB. 5-Aminosalicylic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;94:1075-9. [DOI: 10.1016/0016-5085(88)90569-0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 83] [Article Influence: 3.0] [Reference Citation Analysis]